Gewinnerbranchen der Jahre 2006 bis 2040 (Seite 853)
eröffnet am 10.12.06 16:57:17 von
neuester Beitrag 16.02.24 09:33:08 von
neuester Beitrag 16.02.24 09:33:08 von
Beiträge: 94.068
ID: 1.099.361
ID: 1.099.361
Aufrufe heute: 3
Gesamt: 3.536.327
Gesamt: 3.536.327
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 20:03 | 2106 | |
| heute 18:18 | 1947 | |
| heute 17:30 | 1618 | |
| heute 18:16 | 1561 | |
| heute 18:28 | 1341 | |
| heute 19:46 | 1324 | |
| heute 16:01 | 1155 | |
| vor 1 Stunde | 1096 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.693,37 | +0,01 | 124 | |||
| 2. | 10. | 0,0026 | -72,27 | 67 | |||
| 3. | 2. | 164,81 | -0,08 | 51 | |||
| 4. | 33. | 1,6900 | 0,00 | 47 | |||
| 5. | 4. | 6,4320 | +0,97 | 39 | |||
| 6. | Neu! | 0,3010 | 0,00 | 39 | |||
| 7. | 5. | 9,3500 | -5,65 | 35 | |||
| 8. | 25. | 8,9500 | -2,08 | 35 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 61.000.613 von clearasil am 11.07.19 08:08:51Long Ideas | Healthcare
ADMA Biologics: Significant Derisking, Product Launches In Second Half Of The Year
May 28, 2019 4:05 PM ET|
About: ADMA Biologics, Inc. (ADMA)
This article is exclusive for subscribers.
Jonathan Faison
Shares have lost over a third of their value during the past three years.
Significant derisking has taken place via combination of recent financings and regulatory approvals.
Insider buying and institutional positioning represent two green flags, while supply issues in IVIG market provides significant tailwind for the company's core business.
Launch of ASCENIV and BIVIGAM in the second half of the year provides important near-term catalysts.
I suggest investors with a longer term time frame to initiate a pilot position and patiently accumulate on dips.
Shares of ADMA Biologics (ADMA) have lost over a third over their value over during the past three years. However, the stock has really turned around in 2019 after multiple positive developments, delivering
ADMA Biologics: Significant Derisking, Product Launches In Second Half Of The Year
May 28, 2019 4:05 PM ET|
About: ADMA Biologics, Inc. (ADMA)
This article is exclusive for subscribers.
Jonathan Faison
Shares have lost over a third of their value during the past three years.
Significant derisking has taken place via combination of recent financings and regulatory approvals.
Insider buying and institutional positioning represent two green flags, while supply issues in IVIG market provides significant tailwind for the company's core business.
Launch of ASCENIV and BIVIGAM in the second half of the year provides important near-term catalysts.
I suggest investors with a longer term time frame to initiate a pilot position and patiently accumulate on dips.
Shares of ADMA Biologics (ADMA) have lost over a third over their value over during the past three years. However, the stock has really turned around in 2019 after multiple positive developments, delivering
Neuvorstellung: ADMA - viele Probleme in der Vergangenheit! 
z.B. Probleme mit der Produkionsstätte - sollte jetzt behoben werden.
das Blatt könnte sich jetzt wenden - depressiver Kurs. Ich habe mir mal ein paar geholt.
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
GlobeNewswire•July 8, 2019
All Aspects of the Biotest Therapy Business Unit (“BTBU”) Acquisition Are Successfully Completed
RAMSEY, N.J. and BOCA RATON, Fla., July 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.
“We are very pleased to announce the U.S. License transfer of BIVIGAM® and Nabi-HB® from BPC to ADMA, as this was the final remaining regulatory item from the acquisition of the Biotest Therapy Business Unit transaction,” stated President and Chief Executive Officer, Adam Grossman. “It is important for patients, prescribers and investors to recognize that FDA regulatory licensing is complex, particularly with respect to ADMA’s acquisition of the BTBU assets. Since ADMA’s ownership and operation of the BTBU, we have received an acceptable FDA inspection classification, FDA approvals for two product submissions and now licenses issued in ADMA’s name for two FDA approved biologic drugs. FDA’s license transfer of BIVIGAM® and Nabi-HB® to ADMA’s U.S. License 2019 constitutes a determination by FDA that the establishment and the products meet applicable requirements to ensure the continued safety, purity, and potency of the products. Those applicable requirements also include FDA’s current Good Manufacturing Practice (“cGMP”). Going forward, ADMA will manufacture and introduce both BIVIGAM® and Nabi-HB® into interstate commerce under ADMA’s U.S. License No. 2019 along with its recently approved patented Immune Globulin, ASCENIV®.”
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a vertically integrated biopharmaceutical manufacturer with three FDA approved commercial specialty plasma-based biologics. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations. The target patient populations include immune compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
About Primary Immune Deficiency Disease (“PI”)
PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system. According to the World Health Organization, there are approximately 350 different genetic mutations encompassing PI. Some disorders present at birth or in early childhood, the disorders can affect anyone regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of the system. PI patients are vulnerable to infections and more likely to suffer complications from these infections as compared to individuals with a normal functioning immune system. The infections may occur in any part of the body. Because patients suffering from PI lack a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products. Without this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PI has an estimated prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.
About ASCENIV™ (Formerly referred to as RI-002)
ASCENIV™, Immune Globulin Intravenous, Human – slra 10% Liquid, is a plasma-derived, polyclonal, intravenous immune globulin (“IVIG”). ASCENIV™ is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886. ASCENIV™ is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested using our proprietary microneutralization assay. ASCENIV™ contains naturally occurring polyclonal antibodies. ASCENIV™ is indicated for the treatment of Primary Humoral Immunodeficiency (“PI”) in adults and adolescents (12 to 17 years of age). ADMA received FDA approval for ASCENIV™ on April 1, 2019. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV™ prevented serious bacterial infection among fifty-nine patients treated for twelve months during the pivotal investigation. The most common adverse reactions to ASCENIV™ (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea. ADMA anticipates the commercial launch of ASCENIV™ during the second half of 2019. Certain data and other information about ASCENIV™ or ADMA Biologics and its products can be found on the Company’s website at:
www.admabiologics.com.
Präsentation:
https://d1io3yog0oux5.cloudfront.net/_6913d6a185877f1d0228e7…
z.B. Probleme mit der Produkionsstätte - sollte jetzt behoben werden.das Blatt könnte sich jetzt wenden - depressiver Kurs. Ich habe mir mal ein paar geholt.
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
GlobeNewswire•July 8, 2019
All Aspects of the Biotest Therapy Business Unit (“BTBU”) Acquisition Are Successfully Completed
RAMSEY, N.J. and BOCA RATON, Fla., July 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the United States Food and Drug Administration (“FDA”) has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, (“BPC”) U.S. License No. 1792 and transferred and issued to ADMA’s U.S. License No. 2019.
“We are very pleased to announce the U.S. License transfer of BIVIGAM® and Nabi-HB® from BPC to ADMA, as this was the final remaining regulatory item from the acquisition of the Biotest Therapy Business Unit transaction,” stated President and Chief Executive Officer, Adam Grossman. “It is important for patients, prescribers and investors to recognize that FDA regulatory licensing is complex, particularly with respect to ADMA’s acquisition of the BTBU assets. Since ADMA’s ownership and operation of the BTBU, we have received an acceptable FDA inspection classification, FDA approvals for two product submissions and now licenses issued in ADMA’s name for two FDA approved biologic drugs. FDA’s license transfer of BIVIGAM® and Nabi-HB® to ADMA’s U.S. License 2019 constitutes a determination by FDA that the establishment and the products meet applicable requirements to ensure the continued safety, purity, and potency of the products. Those applicable requirements also include FDA’s current Good Manufacturing Practice (“cGMP”). Going forward, ADMA will manufacture and introduce both BIVIGAM® and Nabi-HB® into interstate commerce under ADMA’s U.S. License No. 2019 along with its recently approved patented Immune Globulin, ASCENIV®.”
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a vertically integrated biopharmaceutical manufacturer with three FDA approved commercial specialty plasma-based biologics. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations. The target patient populations include immune compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
About Primary Immune Deficiency Disease (“PI”)
PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system. According to the World Health Organization, there are approximately 350 different genetic mutations encompassing PI. Some disorders present at birth or in early childhood, the disorders can affect anyone regardless of age or gender. Some affect a single part of the immune system, others may affect one or more components of the system. PI patients are vulnerable to infections and more likely to suffer complications from these infections as compared to individuals with a normal functioning immune system. The infections may occur in any part of the body. Because patients suffering from PI lack a properly functioning immune system, they typically receive monthly treatment with polyclonal immune globulin products. Without this exogenous antibody replacement, these patients would remain vulnerable to persistent and chronic infections. PI has an estimated prevalence of 1:1,200 in the United States, or approximately 250,000 people in the U.S.
About ASCENIV™ (Formerly referred to as RI-002)
ASCENIV™, Immune Globulin Intravenous, Human – slra 10% Liquid, is a plasma-derived, polyclonal, intravenous immune globulin (“IVIG”). ASCENIV™ is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886. ASCENIV™ is manufactured using our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested using our proprietary microneutralization assay. ASCENIV™ contains naturally occurring polyclonal antibodies. ASCENIV™ is indicated for the treatment of Primary Humoral Immunodeficiency (“PI”) in adults and adolescents (12 to 17 years of age). ADMA received FDA approval for ASCENIV™ on April 1, 2019. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV™ prevented serious bacterial infection among fifty-nine patients treated for twelve months during the pivotal investigation. The most common adverse reactions to ASCENIV™ (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea. ADMA anticipates the commercial launch of ASCENIV™ during the second half of 2019. Certain data and other information about ASCENIV™ or ADMA Biologics and its products can be found on the Company’s website at:
www.admabiologics.com.
Präsentation:
https://d1io3yog0oux5.cloudfront.net/_6913d6a185877f1d0228e7…
guten morgen!
dürft ich fragen, was ihr im bereich medizintechnik im portfolio bzw. auf der watchlist habt?
bei mir ists aktuell
axonics
dexcom
globus medical
nevro
raysearch
tandem diabetes
varian
irhythm
dürft ich fragen, was ihr im bereich medizintechnik im portfolio bzw. auf der watchlist habt?
bei mir ists aktuell
axonics
dexcom
globus medical
nevro
raysearch
tandem diabetes
varian
irhythm
VELO heute mit Hüpfer nach oben - Grund: US-Präsident Trump will mehr Organspenden im Land!
US-Präsident Donald Trump will Medienberichten zufolge am Mittwoch (US-Zeit) ein neues Dekret präsentieren, mit dem er die Zahl der Organtransplantationen deutlich erhöhen will. Damit sollen im Umkehrschluss die hohen Ausgaben des öffentlichen Gesundheitswesens für Dialysebehandlungen gesenkt werden.
Der „Washington Post“ und „Politico“ zufolge erhofft sich Trump jährlich 17.000 mehr Nierenspenden und 11.000 andere Organe zusätzlich. 2018 wurden in den USA von knapp 11.000 postmortalen und rund 7000 Lebendspenden über 36.500 Organe transplantiert, so die US-Organisation UNOS.
Außerdem neue Richtlinien, damit das „Matching“ von Spender und Empfänger verbessert und die Zuteilung sowie der Transport beschleunigt wird. Letztlich soll so die Zahl verworfener Transplantate verringert werden.
https://www.aerztezeitung.de/politik_gesellschaft/gesundheit…
Ein guter Vorschlag - sogar mit einer Twitternachricht von ihm
US-Präsident Donald Trump will Medienberichten zufolge am Mittwoch (US-Zeit) ein neues Dekret präsentieren, mit dem er die Zahl der Organtransplantationen deutlich erhöhen will. Damit sollen im Umkehrschluss die hohen Ausgaben des öffentlichen Gesundheitswesens für Dialysebehandlungen gesenkt werden.
Der „Washington Post“ und „Politico“ zufolge erhofft sich Trump jährlich 17.000 mehr Nierenspenden und 11.000 andere Organe zusätzlich. 2018 wurden in den USA von knapp 11.000 postmortalen und rund 7000 Lebendspenden über 36.500 Organe transplantiert, so die US-Organisation UNOS.
Außerdem neue Richtlinien, damit das „Matching“ von Spender und Empfänger verbessert und die Zuteilung sowie der Transport beschleunigt wird. Letztlich soll so die Zahl verworfener Transplantate verringert werden.
https://www.aerztezeitung.de/politik_gesellschaft/gesundheit…
Ein guter Vorschlag - sogar mit einer Twitternachricht von ihm
zu CVRS
Corindus Vascular Robotics : Announces First Commercial Installation of CorPath® GRX System in South America
07/09/2019 | 04:21pm EDT
Brazil’s Albert Einstein Jewish Hospital continues reputation as pioneer in medical robotics
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company's technology in its health system’s leading research facilities.
“Our hospital has a long history of innovation and research and is seen as one of the leading medical institutions across Latin America, including in the field of medical robotics. Being the first hospital in the Southern Hemisphere to implement CorPath GRX shows our continued dedication to finding the best possible treatments for our patients,” said Dr. Marcelo Franken, Head of Cardiology, Albert Einstein Jewish Hospital. “This partnership with Corindus is aligned with our vision of the future and will help our recently launched Center of Complex Cardiac Interventions to further our clinical research efforts as we continue to invest in the world’s leading technologies,” said Dr. Pedro Lemos, Head of Interventional Cardiology of the Hospital.
Recent data indicates that approximately 90,000 percutaneous coronary intervention (PCI) procedures are performed each year in Brazil's public health system, a number that increases at a rate of approximately five to seven percent every year. A similar number of privately insured patients undergo PCI procedures in Brazil annually. Additionally, cardiovascular disease is the leading cause of death in Brazil, accounting for 28% of deaths annually. The hospital will implement the system in a clinical research capacity to evaluate the safety and effectiveness of robotics and to support efforts to obtain future regulatory approval by the Brazilian Health Regulatory Agency. Dr. Sidney Klajner, president of the Sociedade Beneficente Israelita Brasileira Albert Einstein, stated, “We are thrilled to, once more, contribute to leading breakthroughs in the health system in the country. Adding Corindus to our portfolio is one of the steps we take towards the excellence that we treasure here at Einstein. The access to robotic procedures in Brazil is limited, not only in the public health system, but in the private, and as one of the precursors in the innovation and specifically in robotics, Einstein is committed to bringing new techniques and systems to bring about this scenario.”
“The demand for robotics based medical procedures in South America is significant and Corindus is proud to partner with one of Brazil’s leading healthcare institutions to introduce this technology,” said Mark Toland, President and Chief Executive Officer of Corindus. “This latest installation marks yet another key milestone in Corindus’ global expansion, which over the past few months includes France, Japan and now Brazil. We are excited about the growing adoption of vascular robotics in South America and across the globe.”
Corindus Vascular Robotics : Announces First Commercial Installation of CorPath® GRX System in South America
07/09/2019 | 04:21pm EDT
Brazil’s Albert Einstein Jewish Hospital continues reputation as pioneer in medical robotics
Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company's technology in its health system’s leading research facilities.
“Our hospital has a long history of innovation and research and is seen as one of the leading medical institutions across Latin America, including in the field of medical robotics. Being the first hospital in the Southern Hemisphere to implement CorPath GRX shows our continued dedication to finding the best possible treatments for our patients,” said Dr. Marcelo Franken, Head of Cardiology, Albert Einstein Jewish Hospital. “This partnership with Corindus is aligned with our vision of the future and will help our recently launched Center of Complex Cardiac Interventions to further our clinical research efforts as we continue to invest in the world’s leading technologies,” said Dr. Pedro Lemos, Head of Interventional Cardiology of the Hospital.
Recent data indicates that approximately 90,000 percutaneous coronary intervention (PCI) procedures are performed each year in Brazil's public health system, a number that increases at a rate of approximately five to seven percent every year. A similar number of privately insured patients undergo PCI procedures in Brazil annually. Additionally, cardiovascular disease is the leading cause of death in Brazil, accounting for 28% of deaths annually. The hospital will implement the system in a clinical research capacity to evaluate the safety and effectiveness of robotics and to support efforts to obtain future regulatory approval by the Brazilian Health Regulatory Agency. Dr. Sidney Klajner, president of the Sociedade Beneficente Israelita Brasileira Albert Einstein, stated, “We are thrilled to, once more, contribute to leading breakthroughs in the health system in the country. Adding Corindus to our portfolio is one of the steps we take towards the excellence that we treasure here at Einstein. The access to robotic procedures in Brazil is limited, not only in the public health system, but in the private, and as one of the precursors in the innovation and specifically in robotics, Einstein is committed to bringing new techniques and systems to bring about this scenario.”
“The demand for robotics based medical procedures in South America is significant and Corindus is proud to partner with one of Brazil’s leading healthcare institutions to introduce this technology,” said Mark Toland, President and Chief Executive Officer of Corindus. “This latest installation marks yet another key milestone in Corindus’ global expansion, which over the past few months includes France, Japan and now Brazil. We are excited about the growing adoption of vascular robotics in South America and across the globe.”
Trading Spotlight
Antwort auf Beitrag Nr.: 60.990.605 von HenryScheinulf am 10.07.19 00:33:52zum Kopfgebrauch anregenderArtikel. 
Antwort auf Beitrag Nr.: 60.977.881 von flying.kangaroo am 08.07.19 17:19:49Dürfte jetzt schnell Richtung $21 laufen
Ich kann das nicht beurteilen. Aber wenn ich davon überzeugt wäre, dass die jetzt zügig Richtung 21$ laufen, dann würde ich sogar zum heutigen Schlusskurs noch kräftig zulangen.
Ich kann das nicht beurteilen. Aber wenn ich davon überzeugt wäre, dass die jetzt zügig Richtung 21$ laufen, dann würde ich sogar zum heutigen Schlusskurs noch kräftig zulangen.
Antwort auf Beitrag Nr.: 60.977.881 von flying.kangaroo am 08.07.19 17:19:49hi hüpfer - zu schade, aber du hattest wirklich sehr lange Zeit dich zu niedrigeren Kursen zu bedienen!
zu BLFS:
The small firm certainly appeared to be delivering on its mission of providing preservation technologies to keep cell-based therapies viable until they are administered to patients. I noted that the company provided best-in-class tools for storage and distribution in the form of CryoStor Freeze Media and HypoThermosol Storage Media. Management had portrayed business operations as growing in a stable manner due to lack of significant commercial competition, well-defended intellectual property and solid relationships with clients by inserting themselves into the manufacturing distribution process.
I stated that if we were to believe, of over 250 potential applications, each one that is approved represents between $0.5 million and $2 million in potential revenue and growth should continue at an over 30% clip (meaning the growth could keep coming for quite some time).
As for catalysts, I pointed to a series of approvals which foretold of a new wave of revenue growth on the horizon. These included approval of Kolon Life Science's Invossa-K Inj (world's first cell and gene therapy for degenerative arthritis) in Korea, FDA approval for CAR-T cell therapy Yescart and a ten-year supply agreement with TissueGene for which the company believed $5 million in revenue was theoretically possible.
Q3 3017 results were encouraging, with gross margins bumping up to 63% (from 57%) and net loss decreasing by 50% to $425,000. Operational expenses decreased 19% to $1.9 million and a $4 million senior credit facility was converted to Series A redeemable preferred stock by the company's largest shareholder, WAVI. Management's guidance was encouraging, with revenue growth in the range of 41% to 34% ($10.8 million to $12 million), up from 20% to 25% prior predicted growth. Management even felt confident enough to issue 2018 guidance, with biopreservation media revenue expected to total $13.6 million to $14.7 million as well as achieve full-year GAAP operating profit. I also noted that other wins for the quarter included 100% year-over-year growth in revenue generated from the regenerative medicine segment ($1.6 million) along with 23 new direct customer wins and initial orders from 14 regenerative medicine companies.
Lastly, I cited valuation stated that if 2018 revenue totaled $14 million, the stock would be trading at five times forward revenue (quite cheap for a growth stock with the kind of prospects the company is potentially looking at). When these types of names are picked up by mainstream investment media and talking heads (IBD for example), momentum tends to pick up and again investors were being offered a unique way to profit in the biotechnology sector without associated drug development risk.
https://seekingalpha.com/article/4273904-biolife-solutions-u…
zu BLFS:
The small firm certainly appeared to be delivering on its mission of providing preservation technologies to keep cell-based therapies viable until they are administered to patients. I noted that the company provided best-in-class tools for storage and distribution in the form of CryoStor Freeze Media and HypoThermosol Storage Media. Management had portrayed business operations as growing in a stable manner due to lack of significant commercial competition, well-defended intellectual property and solid relationships with clients by inserting themselves into the manufacturing distribution process.
I stated that if we were to believe, of over 250 potential applications, each one that is approved represents between $0.5 million and $2 million in potential revenue and growth should continue at an over 30% clip (meaning the growth could keep coming for quite some time).
As for catalysts, I pointed to a series of approvals which foretold of a new wave of revenue growth on the horizon. These included approval of Kolon Life Science's Invossa-K Inj (world's first cell and gene therapy for degenerative arthritis) in Korea, FDA approval for CAR-T cell therapy Yescart and a ten-year supply agreement with TissueGene for which the company believed $5 million in revenue was theoretically possible.
Q3 3017 results were encouraging, with gross margins bumping up to 63% (from 57%) and net loss decreasing by 50% to $425,000. Operational expenses decreased 19% to $1.9 million and a $4 million senior credit facility was converted to Series A redeemable preferred stock by the company's largest shareholder, WAVI. Management's guidance was encouraging, with revenue growth in the range of 41% to 34% ($10.8 million to $12 million), up from 20% to 25% prior predicted growth. Management even felt confident enough to issue 2018 guidance, with biopreservation media revenue expected to total $13.6 million to $14.7 million as well as achieve full-year GAAP operating profit. I also noted that other wins for the quarter included 100% year-over-year growth in revenue generated from the regenerative medicine segment ($1.6 million) along with 23 new direct customer wins and initial orders from 14 regenerative medicine companies.
Lastly, I cited valuation stated that if 2018 revenue totaled $14 million, the stock would be trading at five times forward revenue (quite cheap for a growth stock with the kind of prospects the company is potentially looking at). When these types of names are picked up by mainstream investment media and talking heads (IBD for example), momentum tends to pick up and again investors were being offered a unique way to profit in the biotechnology sector without associated drug development risk.
https://seekingalpha.com/article/4273904-biolife-solutions-u…
Antwort auf Beitrag Nr.: 60.977.521 von clearasil am 08.07.19 16:34:47Leider wurde mein Nachkaufkurs heute Vormittag durch die Meldung nicht ausgeführt 
Dürfte jetzt schnell Richtung $21 laufen - 1,1 Mio Aktien, die BLFS für die Transaktion bietet, sind aktuell $18 Mio wert. Zuvor hatten sie sich auf eine Zahlung in Höhe von mindestens $23 Mio geeinigt. Bleiben 45 Tage Zeit, um den Wert der 1,1 Mio BLFS Aktien auf $21 zu bringen
Dürfte jetzt schnell Richtung $21 laufen - 1,1 Mio Aktien, die BLFS für die Transaktion bietet, sind aktuell $18 Mio wert. Zuvor hatten sie sich auf eine Zahlung in Höhe von mindestens $23 Mio geeinigt. Bleiben 45 Tage Zeit, um den Wert der 1,1 Mio BLFS Aktien auf $21 zu bringen
Durchsuchen
